The rising occurrence of chronic illnesses, including cancer, cardiovascular diseases, and other long-term health conditions, is a major factor driving the healthcare mobility solutions market. The ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...